首页 | 本学科首页   官方微博 | 高级检索  
     

活血化瘀类药物治疗急性脑梗死的疗效及经济学评价
引用本文:冯荣伟,刘婷婷,刘建芳,范艳平. 活血化瘀类药物治疗急性脑梗死的疗效及经济学评价[J]. 西北药学杂志, 2020, 0(1): 139-142
作者姓名:冯荣伟  刘婷婷  刘建芳  范艳平
作者单位:1.中国人民解放军联勤保障部队第980医院
基金项目:河北省中医药管理局科研计划项目(编号:2019192)
摘    要:目的比较5种常用的活血化瘀类药物治疗急性脑梗死的疗效及药物经济学评价,为临床合理选择治疗方案提供参考。方法收集确诊为急性脑梗死且采用活血化瘀药物治疗的住院患者200例为研究对象,根据使用制剂品种均分为5组,分别为血栓通组、灯盏细辛组、丹红组、疏血通组和银杏内酯组,比较分析这5组的治疗效果及药物经济学评价。结果 5组经过治疗后,神经功能损伤的程度(NIHSS)评分、肢体活动的功能和自我护理的能力(Barehel指数)及血液流变学相关指标均得到明显改善(P<0.05),三者的改善程度丹红组效果最好,总有效率(95.0%)最高,银杏内酯组的效果最差;丹红组的不良反应发生率最低;最低成本-效果分析血栓通组的成本效果比(68.38)最低,其次是丹红组,疏血通组的成本效果比(82.70)最高。结论建议使用活血化瘀注射剂在治疗急性脑梗死时,若效果为首要因素,可考虑丹红注射液作为首选药物,若考虑成本效果比,可考虑血栓通注射液作为首选药物。

关 键 词:活血化瘀  药物经济学  不良反应

Efficacy and pharmacy economic analysis of blood-activating stasis-removing drugs for acute cerebral infarction
FENG Rongwei,LIU Tingting,LIU Jianfang,FAN Yanping. Efficacy and pharmacy economic analysis of blood-activating stasis-removing drugs for acute cerebral infarction[J]. Northwest Pharmaceutical Journal, 2020, 0(1): 139-142
Authors:FENG Rongwei  LIU Tingting  LIU Jianfang  FAN Yanping
Affiliation:(The 980th Hospital of Joint Logistics Support Force of Chinese People′s Liberation Army,Shijiazhuang 050081,China)
Abstract:Objective To compare the efficacy and pharmacoeconomic analysis of 5 commonly used blood-activating stasis-removing drugs in the treatment of acute cerebral infarction,and to provide reference for clinical selection of reasonable treatment options.Methods A total of 200 hospitalized patients who were diagnosed with acute cerebral infarction and treated with blood-activating stasis-removing drugs were enrolled in the study.According to the drug preparations,they were divided into 5 groups,i.e.Xueshuantong group,Dengzhanxixin group,Danhong group,Shuxuetong group and Ginkgolides group.The therapeutic effects and pharmacoeconomics were compared and analyzed.Results After treatment,the NIHSS score,index and hemorheology related indexes of Xueshuantong group,Dengzhanxixin group,Danhong group,Shuxuetong group and Ginkgolide group were all significantly improved(P<0.05).However,the improvement of the Danhong group was the best,the total effective rate(95.2%)was the highest.The effect of Ginkgolide group was the worst.The incidence of adverse reactions was the lowest in the Danhong group.The lowest cost-effectiveness ratio was abtained in the Xueshuantong group(68.38),followed by the Danhong group.The cost-effectiveness ratio of the Shuxuetong group was the highest(82.70).Conclusion It was recommended that in the use of blood-activating stasis-removing injections in the treatment of acute cerebral infarction,if the effect was the primary factor,Danhong Injections could consider as the preferred drug,while if considering the effectiveness ratio,Xueshuantong Injections could consider as the preferred drug.
Keywords:blood-activating stasis-removing  pharmacoeconomics  adverse reactions
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号